D R Spriggs

Detection of circulating tumor necrosis factor after endotoxin administration.

A. Cerami, K. Manogue, D. Spriggs, 1988, The New England journal of medicine.

Recombinant human tumor necrosis factor administered as a 24-hour intravenous infusion. A phase I and pharmacologic study.

D. Kufe, D. Spriggs, D. Wilmore, 1988, Journal of the National Cancer Institute.

Phase II study of "dose-dense" high-dose chemotherapy treatment with peripheral-blood progenitor-cell support as primary treatment for patients with advanced ovarian cancer.

E. Venkatraman, L. Norton, R. Barakat, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phospholipase A2 activation and autoinduction of tumor necrosis factor gene expression by tumor necrosis factor.

D. Kufe, D. Spriggs, M. Mohri, 1990, Cancer research.